Ethnicity and Prescription Patterns for Haloperidol, Risperidone, and Olanzapine

Psychiatric Services

Volumn 55, Issue 2, 2004, Pages 151-156

  Opolka, Jayme L ^a,d   Rascati, Karen L ^b   Brown, Carolyn M ^b   Gibson, P J ^c,d  

^a TAKEDA PHARMACEUTICALS   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c Marion County Health Department   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADULT; AFRICAN AMERICAN; ARTICLE; CAUCASIAN; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; ETHNOLOGY; FEMALE; HEALTH CARE UTILIZATION; HISPANIC; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAID; PATIENT COMPLIANCE; PRESCRIPTION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA;

EMPIRICAL APPROACH; MENTAL HEALTH THERAPIES; PROFESSIONAL PATIENT RELATIONSHIP;

ADULT; AFRICAN AMERICANS; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DRUG UTILIZATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; HALOPERIDOL; HISPANIC AMERICANS; HUMANS; LOGISTIC MODELS; MEDICAID; MIDDLE AGED; MINORITY GROUPS; MULTIVARIATE ANALYSIS; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES; RISPERIDONE; SCHIZOPHRENIA; TEXAS; UNITED STATES;

EID: 0842266727     PISSN: 10752730     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ps.55.2.151     Document Type: Article

References (28)

1. Lillie-Blanton M, Hoffman C: Racial and ethnic inequities in access to medical care: introduction. Medical Care Research and Review 57(suppl 1):5-10, 2000
2. Fabrega H, Mezzich J, Ulrich RF: African-American-white differences in psychopathology in an urban psychiatric population. Comprehensive Psychiatry 29:285-297, 1988
3. Lawson WB: Racial and ethnic factors in psychiatric research. Hospital and Community Psychiatry 37:50-54, 1986
4. Morse JK, Johnson DJ, Heyliger SO: Understanding ethnic disparities in the treatment of affective disorders. Minority Health Today 2:24-27, 2000
5. Adebimpe VR: Race, racism, and epidemiological surveys. Hospital and Community Psychiatry 45:27-31, 1994
6. Jeste DV, Lindamer LA, Evans J, et al: Relationship of ethnicity and gender to schizophrenia and pharmacology of neuroleptics. Psychopharmacology Bulletin 32:243-251, 1996
7. Loring M, Powell B: Gender, race, and DSM-III: a study of the objectivity of psychiatric diagnostic behavior. Journal of Health and Social Behavior 29:1-22, 1988
8. Neighbors HW, Trierweiler SJ, Munday C, et al: Psychiatric diagnosis of African Americans: diagnostic divergence in clinician-structured and semistructured interviewing conditions. Journal of the National Medical Association 91:601-612, 1999
9. Walkup JT, McAlpine DD, Olfson M, et al: Patients with schizophrenia at risk for excessive antipsychotic dosing. Journal of Clinical Psychiatry 61:344-348, 2000
10. Burroughs VJ, Maxey RW, Levy RA: Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment. Journal of the National Medical Association 94:1-26, 2002
11. Worrel, JA, Marken PA, Beckman SE, et al: A typical antipsychotic agents: a critical review. American Journal of Health-System Pharmacists 57:238-258, 2000
12. Leucht S, Pitschel-Walz G, Abraham D, et al: Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophrenia Research 35:51-68, 1999
13. Frankenburg FR: Choices in antipsychotic therapy in schizophrenia. Harvard Review of Psychiatry 6:241-249, 1999
14. Purdon SE, Jones BDW, Stip E, et al: Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Archives of General Psychiatry 57:249-258, 2000
15. Edgell ET, Andersen SW, Johnstone BM, et al: Olanzapine versus risperidone: a prospective comparison of clinical and economic outcomes in schizophrenia. Pharmacoeconomics 18:567-579, 2000
16. Kendrick T: The newer, "atypical" antipsychotic drugs-their development and current therapeutic use. British Journal of General Practice 49:745-749, 1999
17. Foster RH, Goa KL: Olanzapine: a pharmacoeconomic review of its use in schizophrenia. Pharmacoeconomics 15:611-640, 1999
18. Lawson WB: Clinical issues in the pharmacotherapy of African-Americans. Psychopharmacology Bulletin 32:275-281, 1996
19. Kuno E, Bothbard A: Racial disparities in antipsychotic prescription patterns for patients with schizophrenia. American Journal of Psychiatry. 159:567-572, 2002
20. SPSS 10.0 for Windows, SPSS Inc, Chicago, 1999
21. Frackiewicz EJ, Sramek JJ, Collazo Y, et al: Risperidone in the treatment of Hispanic schizophrenic patients, in Cross Cultural Psychiatry, Edited by Herrera JM, Lawson WB, Sramek JJ. England, Wiley, 1999
22. Blazer DG, Hybels CF, Simonsick EM, et al: Marked differences in antidepressant use by race in an elderly community sample: 1986-1996. American Journal of Psychiatry 157:1089-1094, 2000
23. Melfi C, Croghan T, Hanna M, et al: Racial variation in antidepressant treatment in a Medicaid population. Journal of Clinical Psychiatry 61:16-21, 1997
24. Ren XS, Amick BC, Williams DR: Racial/ethnic disparities in health: the interplay between discrimination and socioeconomic status. Ethnicity and Disease 9:151-165, 1999
25. Williams DR, Yu Y, Jackson JS: Racial differences in physical and mental health. Journal of Health Psychology 2:335-351, 1997
26. Buckley PF: Broad therapeutic uses of atypical antipsychotic medicat ions. Biological Psychiatry 50:912-924, 2001
27. Volavka J, Czobor P, Sheitman B, et al: Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. American Journal of Psychiatry 159:255-262, 2002
28. Seeman P: Atypical antipsychotics: mechanism of action. Canadian Journal of Psychiatry 47:27-38, 2002